Zai Lab Limited (HKG:9688)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 28.65B |
| Revenue (ttm) | 3.10B |
| Net Income (ttm) | -2.00B |
| Shares Out | n/a |
| EPS (ttm) | -20.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,495,684 |
| Average Volume | 11,620,646 |
| Open | 26.30 |
| Previous Close | 26.00 |
| Day's Range | 25.40 - 26.90 |
| 52-Week Range | 12.12 - 32.50 |
| Beta | 1.09 |
| RSI | 52.70 |
| Earnings Date | May 8, 2025 |
About Zai Lab
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter... [Read more]
Financial Performance
In 2024, Zai Lab's revenue was $398.99 million, an increase of 49.59% compared to the previous year's $266.72 million. Losses were -$257.10 million, -23.17% less than in 2023.
Financial numbers in USD Financial StatementsNews
Zai Lab gets China's acceptance for label expansion of repotrectinib
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the supplemental New ...
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company's internally discovered and developed next-ge...
Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
ZLAB's Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB's main growth drivers. ZLAB's ongoing strategy of focusing on Chinese approval...
Zai Lab gets China review for Pfizer-partnered cervical cancer therapy
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License...
Insider Sell: Richard Gaynor Sells 2,500 Shares of Zai Lab Ltd (ZLAB)
Insider Sell: Richard Gaynor Sells 2,500 Shares of Zai Lab Ltd (ZLAB)
Zai Lab Announces Participation in Investor Conferences in March 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor...
Decoding Zai Lab Ltd (ZLAB): A Strategic SWOT Insight
Decoding Zai Lab Ltd (ZLAB): A Strategic SWOT Insight
Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript
Zai Lab Limited 2024 Q4 - Results - Earnings Call Presentation
The following slide deck was published by Zai Lab Limited in conjunction with their 2024 Q4 earnings call.
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025
On Thursday, NovoCure Ltd (NASDAQ: NVCR) reported a fourth-quarter loss of 61 cents, down from the 45-cent loss reported a year ago, missing the consensus loss of 34 cents . Sales increased 21% year ...
China Biotech's Sales Jump 66% But Bottom Line Misses Views
Zai Lab pulled back after the biopharmaceutical reported fourth-quarter results. The biotech is building a cup base.
Zai Lab Ltd (ZLAB) Q4 2024 Earnings: EPS Loss of $0.08 Beats Estimates, Revenue at $109. ...
Zai Lab Ltd (ZLAB) Q4 2024 Earnings: EPS Loss of $0.08 Beats Estimates, Revenue at $109.1M Misses Expectations
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highligh...
Zai Lab Q4 2024 Earnings Preview
Janus Henderson Group PLC Significantly Increases Stake in Zai Lab Ltd
Janus Henderson Group PLC Significantly Increases Stake in Zai Lab Ltd
Wellington Management Group LLP's Strategic Acquisition in Zai Lab Ltd
Wellington Management Group LLP's Strategic Acquisition in Zai Lab Ltd
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent ...
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-131...
Chinese regulators accept Zai Lab application for KarXT
Chinese regulators have accepted Zai Lab's market application for the schizophrenia drug KarXT, which is marketed by Bristol-Myers in the U.S. as Cobenfy. Read more here.
Zai Lab Ltd (ZLAB) Announces NDA Acceptance for KarXT in China
Zai Lab Ltd (ZLAB) Announces NDA Acceptance for KarXT in China
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Applicat...